HALOZYME THERAPEUTICS, INC. Quarterly Operating Lease, Payments in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Halozyme Therapeutics, Inc. quarterly/annual Operating Lease, Payments history and growth rate from Q1 2018 to Q3 2024.
  • Halozyme Therapeutics, Inc. Operating Lease, Payments for the quarter ending September 30, 2024 was $1.6M, unchanged year-over-year.
  • Halozyme Therapeutics, Inc. Operating Lease, Payments for the twelve months ending September 30, 2024 was $6.8M, a 4.62% increase year-over-year.
  • Halozyme Therapeutics, Inc. annual Operating Lease, Payments for 2023 was $6.7M, a 59.5% increase from 2022.
  • Halozyme Therapeutics, Inc. annual Operating Lease, Payments for 2022 was $4.2M, a 55.6% increase from 2021.
  • Halozyme Therapeutics, Inc. annual Operating Lease, Payments for 2021 was $2.7M, a 15.6% decline from 2020.
Operating Lease, Payments, Trailing 12 Months (USD)
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $6.8M $1.6M $0 0% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $6.8M $1.7M $0 0% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $6.8M $1.8M +$100K +5.88% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $6.7M $1.7M +$200K +13.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $6.5M $1.6M +$500K +45.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $6M $1.7M +$800K +88.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $5.2M $1.7M +$1M +143% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $4.2M $1.5M +$800K +114% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 $3.4M $1.1M +$500K +83.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $2.9M $900K +$200K +28.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $2.7M $700K $0 0% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $2.7M $700K $0 0% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 $2.7M $600K -$200K -25% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $2.9M $700K -$200K -22.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $3.1M $700K -$100K -12.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $3.2M $700K -$100K -12.5% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-21
Q3 2020 $3.3M $800K $0 0% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 $3.3M $900K +$100K +12.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $3.2M $800K +$100K +14.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $3.1M $800K +$100K +14.3% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-22
Q3 2019 $3M $800K +$100K +14.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 $2.9M $800K +$200K +33.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $2.7M $700K +$300K +75% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $2.4M $700K Oct 1, 2018 Dec 31, 2018 10-K 2020-02-24
Q3 2018 $700K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $600K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $400K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.